Naftidrofuryl oxalate can now be prescribed on the NHS for the treatment of intermittent claudication caused by peripheral arterial disease (PAD). It may be used in patients for whom vasodilator therapy is considered appropriate.
Although naftidrofuryl oxalate does not halt the progression of PAD, it is believed to be the most clinically and cost effective treatment option in terms of improving maximum walking distance.
NICE rejected the other vasodilators cilostazol, pentoxifylline and inositol nicotinate for intermittent claudication in PAD on the grounds that they are not as clinically effective compared with placebo as naftidrofuryl oxalate.
View naftidrofuryl drug record